The HIRA deliberated on benefits for Rinvoq & Kisqali

The results of the review by the Pharmaceutical Benefits Advisory Committee were announced

The HIRA (Director Sun-min Kim) deliberated on the adequacy of benefits for these two new drugs at the Pharmaceutical Benefits Advisory Committee held on the 6th and concluded that AbbVie Korea's new drug for rheumatoid arthritis 'Rinvoq ER 15mg (Upadacitinib)' was to be eligible for reimbursement, and Novartis’ advanced or metastatic breast cancer drug 'Kisqali 200mg (Ribociclib)' gives reimbursed benefit if the evaluation amount is received or less.

 

Rinvoq ER 15mg is a drug used for the treatment of moderate to severe active rheumatoid arthritis in adults who do not respond adequately to one or more antirheumatic drugs (DMARDs) or tolerate it.

 

It is a drug that is administered orally at 15mg once a day regardless of meals, and its ease of use is improved compared to the TNF alpha-blocking injection, which is often used in patients with rheumatoid arthritis.

 

The drug has proven effective in patients with rheumatoid arthritis in 5 cases of phase III clinical trials.

 

In addition, it showed a better response rate compared to control drugs such as MTX monotherapy or placebo group.

 

Kisqali 200mg was approved in Korea on October 30 last year as a combination therapy ▲with aromatase inhibitors as the first endocrine therapy in pre-menopausal, postmenopausal, or postmenopausal women, ▲ with Fulvestrant when the disease progresses after the first endocrine therapy or endocrine therapy in postmenopausal women in advanced or metastatic breast cancer patients with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative.

 

According to this result, Rinvoq ER 15mg will immediately enter into a drug price negotiation with the HIRA in accordance with the order for drug price negotiations from the MOHW.

 

They may step on or remain non-reimbursed or challenge themselves to be reimbursed again.